革兰氏阴性菌中获得性黏菌素耐药性的维持
Preservation of Acquired Colistin Resistance in Gram-Negative Bacteria.
作者信息
Lee Ji-Young, Choi Myung-Jin, Choi Hyeon Jin, Ko Kwan Soo
机构信息
Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea.
Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea
出版信息
Antimicrob Agents Chemother. 2015 Oct 12;60(1):609-12. doi: 10.1128/AAC.01574-15. Print 2016 Jan.
Abstract
Colistin-resistant mutants were obtained from 17 colistin-susceptible strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. The stability of colistin resistance in these mutants was investigated. Three of four colistin-resistant P. aeruginosa mutants recovered colistin susceptibility in colistin-free medium; however, colistin-susceptible revertants were obtained from only one strain each of A. baumannii and E. coli. No susceptible revertants were obtained from K. pneumoniae mutants.
摘要
从17株对黏菌素敏感的鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌和大肠杆菌中获得了耐黏菌素突变体。研究了这些突变体中耐黏菌素的稳定性。4株耐黏菌素的铜绿假单胞菌突变体中有3株在无黏菌素培养基中恢复了对黏菌素的敏感性；然而，仅从1株鲍曼不动杆菌和1株大肠杆菌中获得了对黏菌素敏感的回复突变体。未从肺炎克雷伯菌突变体中获得敏感回复突变体。
相似文献
1
Preservation of Acquired Colistin Resistance in Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2015 Oct 12;60(1):609-12. doi: 10.1128/AAC.01574-15. Print 2016 Jan.
2
Structural Modification of Lipopolysaccharide Conferred by in Gram-Negative ESKAPE Pathogens.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00580-17. Print 2017 Jun.
3
Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
Int J Antimicrob Agents. 2014 Nov;44(5):475-6. doi: 10.1016/j.ijantimicag.2014.07.015.
4
Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
Int J Infect Dis. 2019 Aug;85:10-15. doi: 10.1016/j.ijid.2019.05.004. Epub 2019 May 14.
5
Resistance to polymyxins in Gram-negative organisms.
Int J Antimicrob Agents. 2017 May;49(5):526-535. doi: 10.1016/j.ijantimicag.2016.11.029. Epub 2017 Feb 3.
6
Susceptibility of Colistin-Resistant, Gram-Negative Bacteria to Antimicrobial Peptides and Ceragenins.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00292-17. Print 2017 Aug.
7
The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli.
Int J Antimicrob Agents. 2019 Oct;54(4):507-512. doi: 10.1016/j.ijantimicag.2019.07.006. Epub 2019 Jul 9.
8
Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli: a multicentre study.
Clin Microbiol Infect. 2020 Oct;26(10):1413.e1-1413.e7. doi: 10.1016/j.cmi.2020.01.026. Epub 2020 Jan 30.
9
Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates.
J Antimicrob Chemother. 2014 Jan;69(1):275-7. doi: 10.1093/jac/dkt315. Epub 2013 Aug 29.
10
Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.
Crit Care Med. 2008 Mar;36(3):807-11. doi: 10.1097/CCM.0B013E3181652FAE.
引用本文的文献
1
Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing .
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0076224. doi: 10.1128/aac.00762-24. Epub 2024 Oct 4.
2
Resensitization to colistin results in rapid and stable recovery of adherence, serum resistance and ompW in Acinetobacter baumannii.
PLoS One. 2024 Aug 28;19(8):e0309307. doi: 10.1371/journal.pone.0309307. eCollection 2024.
3
IS-mediated chromosomal amplification of the operon leads to polymyxin B resistance in B strains.
mBio. 2024 Jul 17;15(7):e0063424. doi: 10.1128/mbio.00634-24. Epub 2024 Jun 21.
4
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.
Sci Rep. 2024 May 22;14(1):11706. doi: 10.1038/s41598-024-61518-0.
5
Influence of PhoPQ and PmrAB two component system alternations on colistin resistance from non-mcr colistin resistant clinical E. Coli strains.
BMC Microbiol. 2024 Apr 2;24(1):109. doi: 10.1186/s12866-024-03259-8.
6
Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance.
Nat Commun. 2023 Sep 1;14(1):5311. doi: 10.1038/s41467-023-40828-3.
7
Critical role of the RpoE stress response pathway in polymyxin resistance of Escherichia coli.
J Antimicrob Chemother. 2023 Mar 2;78(3):732-746. doi: 10.1093/jac/dkad003.
8
heteroresistance to levofloxacin caused by upregulated expression of essential genes for DNA replication and repair.
Front Microbiol. 2022 Dec 23;13:1105921. doi: 10.3389/fmicb.2022.1105921. eCollection 2022.
9
Prevalence of polymyxin resistance through the food chain, the global crisis.
J Antibiot (Tokyo). 2022 Apr;75(4):185-198. doi: 10.1038/s41429-022-00502-0. Epub 2022 Jan 26.
10
Genomic Characterization of -Producing Recovered From Human Infections in São Paulo, Brazil.
Front Microbiol. 2021 Jun 9;12:663414. doi: 10.3389/fmicb.2021.663414. eCollection 2021.
本文引用的文献
1
Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains.
Antimicrob Agents Chemother. 2015 Nov;59(11):6763-73. doi: 10.1128/AAC.00952-15. Epub 2015 Aug 17.
2
Antimicrobial heteroresistance: an emerging field in need of clarity.
Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14.
3
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria.
Front Microbiol. 2014 Nov 26;5:643. doi: 10.3389/fmicb.2014.00643. eCollection 2014.
4
Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance.
Antimicrob Agents Chemother. 2015 Jan;59(1):536-43. doi: 10.1128/AAC.04037-14. Epub 2014 Nov 10.
5
Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study.
Int J Antimicrob Agents. 2014 Dec;44(6):500-7. doi: 10.1016/j.ijantimicag.2014.07.020. Epub 2014 Sep 6.
6
The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae.
J Antimicrob Chemother. 2015 Jan;70(1):75-80. doi: 10.1093/jac/dku323. Epub 2014 Sep 3.
7
MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin.
Antimicrob Agents Chemother. 2014 Oct;58(10):5696-703. doi: 10.1128/AAC.03110-14. Epub 2014 Jul 14.
8
Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates.
Diagn Microbiol Infect Dis. 2014 Mar;78(3):271-6. doi: 10.1016/j.diagmicrobio.2013.11.027. Epub 2013 Dec 7.
9
Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2014;58(2):828-32. doi: 10.1128/AAC.01439-13. Epub 2013 Nov 18.
10
Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates.
J Antimicrob Chemother. 2014 Jan;69(1):275-7. doi: 10.1093/jac/dkt315. Epub 2013 Aug 29.
Zotero 插件